Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Neurologic events (NEs) have been reported during treatment with blinatumomab, a bispecific T cell engager (BiTE®) construct. We evaluated the occurrence, severity, and management of NEs; the relationship between NEs and blinatumomab dose; and the potential clinical risk factors in an open-label, si...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Anthony S., Schiller, Gary, Benjamin, Ramsis, Jia, Catherine, Zhang, Alicia, Zhu, Min, Zimmerman, Zachary, Topp, Max S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334725/
https://www.ncbi.nlm.nih.gov/pubmed/30238148
http://dx.doi.org/10.1007/s00277-018-3497-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334725/
https://www.ncbi.nlm.nih.gov/pubmed/30238148
http://dx.doi.org/10.1007/s00277-018-3497-0

Ejemplares similares